FindTrial
Sign In

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04457687
Enrollment
Unknown
Registered
2020-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Resistant Epilepsy, Epilepsies, Myoclonic

Keywords

Extended Access Program, Expanded Access Program, Dravet Syndrome, Refractory Epilepsies, Lorcaserin

Brief summary

The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.

Interventions

DRUGLorcaserin

Lorcaserin 10 milligram (mg) tablets orally.

Sponsors

Eisai Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum

Inclusion criteria

1. Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the treating physician) 2. Male or female, age at least 2 years at the time of informed consent 3. Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304 4. Has a clinical benefit from lorcaserin in the opinion of the treating physician

Exclusion criteria

None

Countries

Canada, United States

Contacts

Primary ContactEisai Medical Information
esi_medinfo@eisai.com+1-888-274-2378

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026